Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190018/S052

Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon ToricAspheric Hydrophobic Acrylic Intraocular Lens

Alcon Laboratories, LLC · Decision date Jul 2, 2026

FDA DECISIONP190018/S052

What did the FDA decide?

FDA records P190018/S052 as a supplement to PMA P190018, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 2, 2026.

FDA approval order statement

a change to the image quality and IOL power measurement equipment for Clareon and AcrySof multifocal IOLs
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Jul 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P190018/S052
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
OK30
Decision date
Jul 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

For the original device and its historical approval scope, see PMA P190018. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190018 · Original PMA

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens

  2. P190018/S042 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon ToricAspheric Hydrophobic Acrylic Intraocular Lens,

  3. P190018/S043 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon ToricAspheric Hydrophobic Acrylic Intraocular Lens,

  4. P190018/S044 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Le

  5. P190018/S045 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) and Clareon PanOptix Hydrophobic Acrylic IOL

  6. P190018/S047 · Related supplement

    Clareon TruPlus Aspheric Hydrophobic Acrylic Intraocular Lens (IOL); Clareon TruPlus Toric Aspheric Hydrophobic Acrylic

  7. P190018/S049 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) and Clareon PanOptix Hydrophobic Acrylic IOL

  8. P190018/S048 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic IOL (SY60WF); Clareon Aspheric UV Absorbing IOL (CC60WF); Clareon Toric Aspheric UV

  9. P190018/S046 · Related supplement

    Clareon Vivity Toric Extended Vision UV Absorbing Hydrophobic Intraocular Lens (IOL)

  10. P190018/S052 received

    Application receipt date recorded by FDA.

  11. P190018/S054 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Le

  12. P190018/S052 · FDA decision

    30-Day Notice

  13. P190018/S053 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens

  14. P190018/S051 · Related supplement

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens with the AutonoMe Pre- Loaded Delivery System, Clareon Toric Asphe

  15. P190018/S050 · Related supplement

    Clareon Vivity Pro Extended Vision IOLs

Timeline entries are records held by MedtechLedger for P190018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190018

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Laboratories, LLCPMA approvalJan 7, 2020FDA
Alcon Laboratories, LLCPMA supplementJul 18, 2025FDA
Alcon Laboratories, LLCPMA supplementAug 25, 2025FDA
Alcon Laboratories, LLCPMA supplementSep 18, 2025FDA
Alcon Laboratories, LLCPMA supplementDec 12, 2025FDA
Alcon Laboratories, LLCPMA supplementFeb 19, 2026FDA
Alcon Laboratories, LLCPMA supplementMar 2, 2026FDA
Alcon Laboratories, LLCPMA supplementApr 30, 2026FDA
Alcon Laboratories, LLCPMA supplementMay 15, 2026FDA
Alcon Laboratories, LLCPMA supplementJul 2, 2026FDA
Alcon Laboratories, LLCPMA supplementJul 6, 2026FDA
Alcon Laboratories, LLCPMA supplementAug 17, 2026FDA
Alcon Laboratories, LLCPMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Laboratories, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy., Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records